EXPERIMENTAL RESEARCH
Pathophysiology
doi: 10.25005/2074-0581-2024-26-3-407-416
NANOPARTICULATE BDNF AS A POTENTIAL ANTIDEPRESSANT VIA NEUROENDOCRINE MECHANISMS IN EXPERIMENTAL MODEL OF DEPRESSION

N.A.D. BINTI RAZLAN1, M. KAPITONOVA1, S.B. TALIP1, N. RAMLI1, I.B. BROHI1, T.M. NWE2, R.N. ALYAUTDIN3, R.N. ALYAUTDIN3,4

1Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kota Samarahan, Malaysia
2Royal College of Medicine, UniKL, Ipoh, Malaysia
3I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
4Scientific Center of Expertise of Medical Products, Moscow, Russian Federation

Objective: To study the effect of a nanoparticulate brain-derived neurotrophic factor with surfactant (BDNF) on the modeled depression not associated with stress in mice

Methods: Thirty-six C57BL/6 mice weighing 20-25 g were included in the study with reserpine-induced depression. The animals were divided into three groups: Group 1 – negative control, involving animals treated with normal saline, Group 2 – positive control involving animals treated with a traditional antidepressant fluoxetine, and Group 3 – experimental, treated with nanoparticulate BDNF with a surfactant. Open field, sucrose preference, and forced swimming tests were applied in the study, and the ELISA method was used to determine the corticosterone level in the serum. Digital morphometry of the adrenal cortex and thymus was done. SPSS 27.0.1 software was used for statistics, with a p<0.05 level of significance

Results: The mice of the BDNF and fluoxetine groups exhibited meaningfully lower levels of serum corticosterone (p<0.01), and considerable improvements in the open field, sucrose preference, and forced swimming tests (p<0.01) than the animals of the normal saline group. Digital morphometry showed a meaningful reduction in the share of the zona fasciculata in the adrenal gland, the area of its cells, and their nuclei in the BDNF group compared to the animals treated with normal saline (p<0.05). In contrast, the difference between the fluoxetine and normal saline groups was insignificant. A meaningfully higher thymic cortex-medulla ratio was noted in the mice of the BDNF group compared to the normal saline (p<0.01) and fluoxetine (p<0.05) groups, and a lower percentage of macrophages with apoptotic bodies compared to normal saline (p<0.01) and fluoxetine groups (p<0.05), which was not significantly different between the fluoxetine and normal saline groups.

Conclusion: Nanoparticulate BDNF with a surfactant shows the efficacy of treatment of modeled depression comparable with the traditional antidepressant fluoxetine, as evidenced by behavioral tests, decreased corticosterone levels, or even exceeding it, as shown by significantly reduced hyperplasia of the zona fasciculata of the adrenal gland and of its cells, as well as reduced immunosuppressive changes in the thymus (higher corticomedullary ratio, lower volume density of the tingible body macrophages). These results underscore the potential of nanoparticulate BDNF as a treatment for depression not associated with stress.

Keywords: BDNF, PLGA, depression, hypothalamic-pituitary-adrenal axis.

Download file:

References
  1. Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299-312. https://doi. org/10.1016/S0140-6736(18)31948-2
  2. Dodd S, Bauer M, Carvalho AF, Eyre H, Fava M, Kasper S, et al . A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough? World J Biol Psychiatry. 2021;22:483-94. https://doi.org/10.1080/15622975.2020.1851052
  3. Monroe SM, Harkness KL. Major depression and its recurrences: Life course matters. Annu Rev Clin Psychol. 2022;18:329-57. https://doi.org/10.1146/ annurev-clinpsy-072220-021440
  4. Alizadeh Pahlavani H. Possible role of exercise therapy on depression: Effector neurotransmitters as key players. Behav Brain Res. 2024;459:114791. https:// doi.org/10.1016/j.bbr.2023.114791
  5. Stecher C, Cloonan S, Domino ME. The economics of treatment for depression. Annu Rev Public Health. 2024;45:527-51. https://doi.org/10.1146/annurevpublhealth-061022-040533
  6. Talaee N, Azadvar S, Khodadadi S, Abbasi N, Asli-Pashaki ZN, Mirabzadeh Y, et al. Comparing the effect of fluoxetine, escitalopram, and sertraline, on the level of BDNF and depression in preclinical and clinical studies: A systematic review. Eur J Clin Pharmacol. 2024;80:983-1016. https://doi.org/10.1007/s00228-024- 03680-y
  7. Brigadski T, Leßmann V. The physiology of regulated BDNF release. Cell Tissue Res. 2020;382:15-45. https://doi.org/10.1007/s00441-020-03253-2
  8. Cefis M, Quirié A, Pernet N, Marie C, Garnier P, Prigent-Tessier A. Brain-derived neurotrophic factor is a full endothelium-derived factor in rats. Vascul Pharmacol. 2020;128-129:106674. https://doi.org/10.1016/j.vph.2020.106674
  9. Miranda-Lourenço C, Ribeiro-Rodrigues L, Fonseca-Gomes J, Tanqueiro SR, Belo RF, Ferreira CB, et al. Challenges of BDNF-based therapies: From common to rare diseases. Pharmacol Res. 2020;162:105281. https://doi.org/10.1016/j. phrs.2020.105281
  10. Xue Y, Liang H, Yang R, Deng K, Tang M, Zhang M. The role of pro- and mature neurotrophins in the depression. Behav Brain Res. 2021;404:113162. https://doi. org/10.1016/j.bbr.2021.113162
  11. Fukuyama Y, Kubo M, Harada K. Neurotrophic natural products. Prog Chem Org Nat Prod. 2024;123:1-473. https://doi.org/10.1007/978-3-031-42422-9_1
  12. Colucci-D'Amato L, Speranza L, Volpicelli F. Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci. 2020;21:7777. https://doi.org/10.3390/ijms21207777
  13. Antolasic EJ, Jaehne EJ, van den Buuse M. Interaction of brain-derived neurotrophic factor, exercise, and fear extinction: Implications for post-traumatic stress disorder. Curr Neuropharmacol. 2024;22:543-56. https://doi.org/10.2174/ 1570159X21666230724101321
  14. Sun YX, Su YA, Wang Q, Zheng JY, Zhang CC, Wang T. The causal involvement of the BDNF-TrkB pathway in dentate gyrus in early-life stress-induced cognitive deficits in male mice. Transl Psychiatry. 2023;13(1):173. https://doi.org/10.1038/ s41398-023-02476-5
  15. Lozano-Ureña A, Frade JM. Differential contribution of TrkB and p75(NTR) to BDNF-dependent self-renewal, proliferation, and differentiation of adult neural stem cells. Front Mol Neurosci. 2023;16:1271820. https://doi.org/10.3389/ fnmol.2023.1271820
  16. Yang T, Nie Z, Shu H, Kuang Y, Chen X, Cheng J, et al. The role of BDNF on neural plasticity in depression. Front Cell Neurosci. 2020;14:82. https://doi. org/10.3389/fncel.2020.00082
  17. Miyanishi H, Nitta A. A role of BDNF in the depression pathogenesis and a potential target as antidepressant: The modulator of stress sensitivity ‘shati/ Nat8l-BDNF system’ in the dorsal striatum. Pharmaceuticals. 2021;14:889. https://doi.org/10.3390/ph14090889
  18. Madsen CA, Navarro ML, Elfving B, Kessing LV, Castrén E, Mikkelsen JD, et al. The effect of antidepressant treatment on blood BDNF levels in depressed patients: A review and methodological recommendations for assessment of BDNF in blood. Eur Neuropsychopharmacol. 2024;87:35-55. https://doi.org/10.1016/j. euroneuro.2024.06.008
  19. Ye Z, Wang J, Fang F, Wang Y, Liu Z, Shen C, et al. Zhi-Zi-Hou-Po decoction alleviates depressive-like behavior and promotes hippocampal neurogenesis in chronic unpredictable mild stress induced mice via activating the BDNF/TrkB/ CREB pathway. J Ethnopharmacol. 2024;319:117355. https://doi.org/10.1016/j. jep.2023.117355
  20. Zagrebelsky M, Korte M. Are TrkB receptor agonists the right tool to fulfill the promises for a therapeutic value of the brain-derived neurotrophic factor? Neural Regen Res. 2024;19(1):29-34. https://doi.org/10.4103/1673-5374.374138. PMID:37488840
  21. Zarza-Rebollo JA, López-Isac E, Rivera M, Gómez-Hernández L, Pérez-Gutiérrez AM, Molina E. The relationship between BDNF and physical activity on depression. Prog Neuropsychopharmacol Biol Psychiatry. 2024;134:111033. https://doi.org/10.1016/j.pnpbp.2024.111033
  22. Zhao X, Du Y, Yao Y, Dai W, Yin Y, Wang G, et al. Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice. J Psychopharmacol. 2024;38(5):489-99. https://doi.org/10.1177/02698811241249436
  23. Lampe KJ, Kern DS, Mahoney MJ, Bjugstad KB. The administration of BDNF and GDNF to the brain via PLGA microparticles patterned within a degradable PEGbased hydrogel: Protein distribution and the glial response. J Biomed Mater Res A. 2011;96(3):595-607. https://doi.org/10.1002/jbm.a.33011
  24. Binti Razlan NAD, Kapitonova M, Alyautdin RN, Talip SB, Ramli N, Nwe TM. Experimental depression-modulated activation pattern of the hypothalamicpituitary-adrenal axis. Avicenna Bulletin. 2024;26(1):57-66. https://doi. org/10.25005/2074-0581-2024-26-1-57-66
  25. Kapitonova MY, Alyautdin RN, Wan-Syazli RWAL, Nor-Ashikin MNK, Аhmad A, Norita S, et al. Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism. Bulletin of RSMU. 2018;6:107-12. https://doi. org/10.24075/brsmu.2018.072
  26. Hinkelmann K, Rose M. Stress and depression – a neurobiological perspective. HNO. 2024 Jul 25. https://doi.org/10.1007/s00106-024-01500-4
  27. Menke A. The HPA axis as target for depression. Curr Neuropharmacol. 2024;22:904-15. https://doi.org/10.2174/1570159X21666230811141557
  28. Tsimpolis A, Kalafatakis K, Charalampopoulos I. Recent advances in the crosstalk between the brain-derived neurotrophic factor and glucocorticoids. Front Endocrinol (Lausanne). 2024;15:1362573. https://doi.org/10.3389/ fendo.2024.1362573
  29. . Khalin I, Alyautdin R, Wong TW, Gnanou J, Kocherga G, Kreuter J. Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury. Drug Deliv. 2016;23:3520-8. https://doi.org/10.1080/10 717544.2016.1199609
  30. Kamarudin SN, Iezhitsa I, Tripathy M, Alyautdin R, Ismail NM. Neuroprotective effect of poly(lactic-co-glycolic acid) nanoparticle-bound brain-derived neurotrophic factor in a permanent middle cerebral artery occlusion model of ischemia in rats. Acta Neurobiol Exp (Wars). 2020;80:1-18.

Authors' information:

Binti Razlan Nur Amirah Diyana,
Postgraduate Student, Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak
ORCID ID: 0009-0001-6515-7098
E-mail: amirah6497@gmail.com

Kapitonova Marina,
MD, PhD, Professor, Professor of Anatomy, Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak
Researcher ID: Y-6429-2018
Scopus ID: 8854275100
ORCID ID: 0000-0001-6055-3123
E-mail: kmarina@unimas.my

Talip Saiful Bahri,
MD, Senior Lecturer, Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak
Researcher ID 57191838596
Scopus ID: 57191838596
ORCID ID: 0000-0001-9470-4559
E-mail: tsbahri@unimas.my

Ramli Norhida,
MD, Senior Lecturer, Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak
Researcher ID 56893285800
Scopus ID: 56893285800
ORCID ID: 0000-0002-8764-5340
E-mail: rnorhida@unimas.my

Brohi Imam Bux,
MD, Associate Professor of the Family Medicine, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak
ORCID ID: 0000-0001-7574-2154
E-mail: bimam@unimas.my

Nwe Tin Moe,
MD, PhD, Associate Professor, Royal College of Medicine, Faculty UniKL
Researcher ID 8854275100
Scopus ID: 8854275100
ORCID ID: 0000-0001-6055-3123
E-mail: mntin@unimas.my

Alyautdin Renad Nikolaevich,
MD, PhD, Professor of the Pharmacology Department, I.M. Sechenov First Moscow State Medical University; Head, Scientific Center for Expert Evaluation of Medicinal Products
Researcher ID: L-9261-2014
Scopus ID: 6701792451
ORCID ID: 0000-0002-4647-977X
E-mail: alyautdin@mail.ru

Information about support in the form of grants, equipment, medications

This study was supported by a grant (RDCRG/CAT/2019/17) from the Sarawak Research and Development Council (SRDC). The authors did not receive financial support from manufacturers of medicines and medical equipment

Conflicts of interest: No conflict

Address for correspondence:

Kapitonova Marina,
MD, PhD Professor, Professor of Anatomy, Department of Basic Medical Sciences, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kota Samarahan

Kota Samarahan 94300, Malaysia

Tel.: +60 (176) 243699

E-mail: kmarina@unimas.my

Materials on the topic:
  1. EVALUATION OF PROTEOLYTIC ACTIVITY IN EXPERIMENTAL PERITONITIS WITH SEROGUARD® TREATMENT
  2. MORPHOLOGICAL FEATURES OF PLACENTAS IN PREGNANCIES WITH FETAL GROWTH RESTRICTION SYNDROME
  3. EXPERIMENTAL DEPRESSION-MODULATED ACTIVATION PATTERN OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
  4. EVALUATION OF HEMATOTOXICITY OF NEW DERIVATIVES OF CONDENSED 3-AMINOTHIENO[2,3-b]PYRIDINES AND 1,4-DIHYDROPYRIDINES WITH HIGH ANALGESIC ACTIVITY
  5. LABORATORY BIOMARKERS FOR BRAIN DAMAGE IN DIABETES MELLITUS
  6. EFFECT OF ACTH6-9-PRO-GLY-PRO PEPTIDE ON SPECTRAL PARAMETERS OF HEART RATE VARIABILITY IN WISTAR RATS DURING PHYSICAL EXERTION (PILOT STUDY)
  7. IN VIVO STUDY OF WOUND-HEALING ACTIVITY OF POLYSACCHARIDE GEL WITH ENCAPSULATED SEA-BUCKTHORN OIL (HIPPOPHAE RHAMNOIDES)
  8. DYNAMICS OF DRUG RESISTANCE IN M. TUBERCULOSIS DURING THE NEW CORONAVIRUS INFECTION PANDEMIC IN DUSHANBE: THE NEED FOR URGENT MEASURES
  9. IMPLEMENTATION STUDY IN PREVENTION AND CONTROL OF DRUG-RESISTANT TUBERCULOSIS DURING THE COVID-19 PANDEMIC IN DUSHANBE
  10. PREVALENCE OF MYCOBACTERIUM TUBERCULOSIS AMONG CHILDREN AT THE RESERVOIRS OF INFECTION IN THE REPUBLIC OF TAJIKISTAN

◄ Back to the list